These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15704674)

  • 41. [Efficacy of vaccination against hepatitis B in adult with HIV infection].
    Kalinowska-Nowak A; Bociaga-Jasik M; Garlicki A; Mach T
    Przegl Epidemiol; 2007; 61(2):339-47. PubMed ID: 17956052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines.
    Ferrantelli F; Cafaro A; Ensoli B
    Curr Opin Biotechnol; 2004 Dec; 15(6):543-56. PubMed ID: 15560981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Vaccinations of HIV-infected travelers].
    Couzigou C; Voyer C; Shaghaghi CK; Bourée P; Vittecoq D
    Med Mal Infect; 2009 Jan; 39(1):21-8. PubMed ID: 18723304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunopathogenesis and therapeutic immunization in HIV-infection].
    Kran AM; Kvale D
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3112-6. PubMed ID: 17160117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
    Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S
    Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HBV and HCV infection in Japanese dental care workers.
    Nagao Y; Matsuoka H; Kawaguchi T; Ide T; Sata M
    Int J Mol Med; 2008 Jun; 21(6):791-9. PubMed ID: 18506374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccination against drug resistance in HIV infection.
    Boberg A; Isaguliants M
    Expert Rev Vaccines; 2008 Feb; 7(1):131-45. PubMed ID: 18251699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic effect of an anti-HIV candidate vaccine.
    Lurhuma Z; Wane J; Mbayo K; Karhemere B
    East Afr Med J; 1994 Aug; 71(8):493-5. PubMed ID: 7867538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV vaccines. Controversy continues in Nigeria over supposed preventive and curative vaccine.
    AIDS Wkly; 2000 Aug 14-21; ():18. PubMed ID: 12349804
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune-based therapies in brief.
    Proj Inf Perspect; 2000 Mar; (29):19-20. PubMed ID: 12772669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rebuilding the immune system: promising new therapy uses the HIV virus itself to awaken the damaged immune system. Interview by Brian Coppedge and Dan Dawson.
    Moss R
    STEP Perspect; 1998; 98(2):13-6. PubMed ID: 11365540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The design and testing of HIV prophylactic vaccines.
    Ada G
    AIDS Res Hum Retroviruses; 1992 May; 8(5):758-63. PubMed ID: 1515227
    [No Abstract]   [Full Text] [Related]  

  • 56. Therapeutic vaccination: where are we now?
    Rosenberg ES
    AIDS Clin Care; 2003 Jan; 15(1):1-3. PubMed ID: 12685420
    [No Abstract]   [Full Text] [Related]  

  • 57. [A modern approach to developing anti-HIV vaccines].
    Sergeev OV
    Vopr Virusol; 1997; 42(2):50-3. PubMed ID: 9182397
    [No Abstract]   [Full Text] [Related]  

  • 58. AIDS vaccine efforts have followed long, bumpy road.
    AIDS Alert; 2001 May; 16(5):64-6, 54. PubMed ID: 11590782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Jerimiah Abalaka and HIV in Nigeria.
    Spier RE
    Vaccine; 2004 Sep; 22(29-30):3817-8. PubMed ID: 15364426
    [No Abstract]   [Full Text] [Related]  

  • 60. [Jeremiah Abalaka and his HIV vaccine].
    Huang YF; Lu NQ
    Zhonghua Nan Ke Xue; 2005 Jan; 11(1):7-8. PubMed ID: 15704673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.